P1-0189 — Final report
1.
Pellets containing non-aqueous fluids and the process for their preparation

The present invention relates to pellets and a process for their preparation where polyhydroxy alcohols (glycerol, propileneglycol) are used as agglomerating fluids to avoid water during the manufacturing process of the pellets. The invention is forseen to be very useful in the pharmaceutical industry by processing the water sensible active ingredients. The new pellets form have been named »pelliquets«

F.09 Development of a new technological process or technology

COBISS.SI-ID: 1524081
2.
Organization of annual scientific symposia of Pharmaceutical Technology Section at the Slovenian Pharmaceutical Society

The main purpose is education of pharmacist working in regulatory agencies, academia and industry. We have organized the following symposia: 2004: Nanotechnology in pharmacy, 2005: PAT – Process analytical technology in pharmaceutical and chemical industry, 2006: New excipients and novelties at their application, 2007: Water in dosage forms: necessary, wanted or unwanted component.

B.01 Organiser of a scientific meeting

COBISS.SI-ID: 2140785
3.
Establishment of spin off enterprise IGC Center d.o.o.

Enterprise IGC Center d.o.o. was established in 2005 under patronage of Ljubljana University Incubator and today colaborates with companies in Slovenia and abroad. Strategy rests on knowledge and innovative approaches that were gained during development of inverse gas chromatography and other methods used for physico-chemical characterization of solids, at the Faculty of Pharmacy in Ljubljana. Experiences are sucesfully implemented to pharmaceutical industry in solving their problems. Establishment of spin off enterprises shows direct flow of the knowledge from university to industry.

F.20 Company spin off

COBISS.SI-ID: 2461234
4.
Guest Editor of scientific publication International Journal of Pharmaceutics (A. Mrhar)

Two issues of the journal containing best peer-reviewed full-length articles selected from the contributions presented at the 5th and 4th Central European Symposium on Pharmaceutical Technology and Biodelivery Systems (Ljubljana 2003, Vienna 2001)

C.03 Guest-associated editor

COBISS.SI-ID: 1687665
5.
Projects for pharmaceutical industry

In collaboration with the experts form companies Krka d.d. and Lek d.d., dissolution and permeability studies are being implemented as a part of preformulation and formulation studies that significantly shorten the time needed for the development of new generic drug products and reduce the number of neccessary clinical trials (bioequivalence studies) on healthy volunteers.

F.17 Transfer of existing technologies, know-how, methods and procedures into practice

COBISS.SI-ID: 3691234
6.
Establishment of spin off enterprise IGC Center d.o.o.

Enterprise IGC Center d.o.o. was established in 2005 under patronage of Ljubljana University Incubator and today colaborates with companies in Slovenia and abroad. Strategy rests on knowledge and innovative approaches that were gained during development of inverse gas chromatography and other methods used for physico-chemical characterization of solids, at the Faculty of Pharmacy in Ljubljana. Experiences are sucesfully implemented to pharmaceutical industry in solving their problems. Establishment of spin off enterprises shows direct flow of the knowledge from university to industry.

F.20 Company spin off

7.
Guest Editor of scientific publication International Journal of Pharmaceutics (A. Mrhar)

Two issues of the journal containing best peer-reviewed full-length articles selected from the contributions presented at the 5th and 4th Central European Symposium on Pharmaceutical Technology and Biodelivery Systems (Ljubljana 2003, Vienna 2001)

C.03 Guest-associated editor

8.
Projects for pharmaceutical industry

In collaboration with the experts form companies Krka d.d. and Lek d.d., dissolution and permeability studies are being implemented as a part of preformulation and formulation studies that significantly shorten the time needed for the development of new generic drug products and reduce the number of neccessary clinical trials (bioequivalence studies) on healthy volunteers.

F.17 Transfer of existing technologies, know-how, methods and procedures into practice